北京爱思益普生物科技

Company Overview

ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication and flexible collaboration modes, to speed up drug discovery process better and faster.

ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection.

Currently ICE Bioscience could provide 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, 40+ nuclear receptors assays on shelf with validation data and screening information which has competitive advantage in China covering most of the druggable targets. The company already established multiple platforms for Protein purification, Biochemistry, Immunology, Oncology, Electrophysiology, in vitro Cardiac and CNS Pharmacology, off-target safety evaluation, Cardiac safety evaluation, PK-ADMET etc., we are able to make DMTA cycle (Design-Make-Test-Analysis cycle) running smoothly for innovative drug discovery together with client. We have successfully collaborated with 600+ clients in the past and got wide acclaim.

ICE Bioscience has 7000 m2 lab in two buildings, 160 members by the end of 2021, with state-of-the-art instruments costed >8 million $, two Oversea High-level Talents and Beijing Distinguished Experts major on CNS and Cardiac fields. ICE Bioscience also gained National High-tech Enterprises and Z-PARK High Tech Enterprise titles according to the effort on innovative research. We successfully supported more than 300 biotech companies and >10 IND studies in 2021, now we are expanding quickly and hope to give higher quality service for more clients and collaborate with more entities focusing on innovative studies in 2022.

北京爱思益普生物科技股份有限公司2010 年成立，专注于从先导化合物筛选，优化到临床前候选分子阶段基于细胞和生化的药物体外筛选技术和早期药物机理研究，关注肿瘤，免疫，心血管，中枢神经系统等疾病领域的生物学和药理学研究技术，打造创新型CRO+的探索者。爱思益普关注新药研发企业对速度、效率和结果的需求，用专业的技术和高效的沟通帮助客户提高新药研发的效率。

爱思益普致力于建立全面的靶点筛选和体外生物学研究平台，建立一系列基于生物学和药理学的研究技术集群，为客户提供涵盖各种靶标和疾病领域的新药研发服务，包括从活性化合物发现，靶标验证，先导化合物优化到临床前候选药物的选择。公司建立了100+离子通道，100+GPCR，800+酶学靶点以及40+核受体筛选细胞系及验证方法，涵盖了大部分成药性靶点，在国内具有领先水平和竞争优势。公司建立了蛋白纯化，生化酶学，肿瘤细胞学，免疫学，电生理学，心脏体外研究，中枢神经系统药理学，药物脱靶效应筛选，药物心脏安全性评价，ADME等平台，全面支持创新药研发的DMTA（设计，合成，测试，分析）一体化服务。爱思益普为国内新药研发机构超过600家以上机构提供服务，得到客户广泛好评。

爱思益普目前拥有7000平方米实验室，160多名员工，仪器设备投入超过5000万元，2人入选北京市“海聚工程”海外高层次人才及北京市特聘专家。是国家高新技术企业，中关村高新技术企业。2021年服务全国创新药研发生物科技企业超过300家，每年数十个项目进行新药临床研究（IND）申报，多个项目通过NMPA的现场核查。